ClinicalTrials.gg
CompletedNCT05096208Updated Apr 12, 2023Results posted

Clinical Lot Consistency for RSVpreF in a Population of Healthy Adults 18 to ≤49 Years of Age

A Phase 3 interventional study of RSVpreF (Group 1) and RSVpreF (Group 2) in RSV, sponsored by Pfizer. Completed at 18 sites in United States. Open to participants aged 18 Years to 49 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-04-12.

Sponsored by Pfizer · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,028
Allocation
Randomized
Ages
18 Years to 49 Years
Sex
All
01

Study summary

This randomized, double-blinded, placebo-controlled Phase 3 study is designed to evaluate the safety, tolerability, and immunogenicity of 3 lots of RSVpreF in healthy adults.

Read the detailed description

This randomized, double-blinded, placebo-controlled Phase 3 study will examine the immune response and the safety and tolerability profiles across 3 manufactured lots of RSVpreF when administered as a single 120 µg dose to healthy adults to demonstrate lot equivalence in manufacturing of RSVpreF.

02

Conditions studied

  • RSV

Keywords

  • RSV
  • Vaccine
03

In context

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 49 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy males or nonpregnant, nonbreastfeeding females between the ages of 18 and ≤49 years, inclusive, at Visit 1 (Day 1).
  2. Participants who are willing and able to comply with scheduled visits, laboratory tests, lifestyle considerations, and other study procedures, including daily completion of the e diary for 7 days after study vaccination.
  3. Healthy participants as determined by medical history, physical examination (if required), and the clinical judgment of the investigator to be eligible for inclusion in the study. Participants with preexisting chronic medical conditions determined to be stable in the clinical judgment of the investigator may be included.
  4. Capable of giving signed as described in the protocol, which includes compliance with the requirements and restrictions listed in the ICD and in the protocol.

Exclusion criteria

Exclusion Criteria:

  1. Bleeding diathesis or condition associated with prolonged bleeding time that may contraindicate IM injection.
  2. History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the study intervention or any related vaccine.
  3. Unstable chronic medical condition or disease requiring significant change in therapy or hospitalization for worsening disease within 3 months before receipt of study intervention.
  4. individuals with known or suspected immunodeficiency, as determined by history and/or laboratory/physical examination.
  5. Known infection with , , or .
  6. Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
  7. Previous vaccination with any licensed or RSV vaccine at any time prior to enrollment or planned receipt throughout the study.
  8. Receipt of any blood/plasma products or immunoglobulin, from 60 days before study intervention administration or planned receipt throughout the study.
  9. Receipt of monoclonal antibodies from 60 days before study intervention administration or planned receipt throughout the study.
  10. Receipt of systemic treatment with known immunosuppressant medications within 60 days before study intervention administration or the use of systemic (≥20 mg/day of prednisone or equivalent) for ≥14 days within 28 days prior to study enrollment. Prednisone use of \<20 mg/day for \<14 days is permitted. Inhaled/nebulized, intra-articular, intrabursal, or topical (skin, eyes, ears) corticosteroids are permitted.
  11. Current alcohol abuse or illicit drug use. Note: Marijuana use is not considered an exclusion criterion for the study when elicited in participant screening, though it may be considered illicit in some locales.
  12. Current use of any prohibited concomitant medication(s) or those unwilling/unable to use a permitted concomitant medication(s).
  13. Participation in other studies involving investigational drug(s) or investigational vaccines within 28 days prior to consent and/or during study participation.
  14. Pregnant females; breastfeeding females; and women of child bearing potential who are unwilling or unable to use a highly effective method of as outlined in the protocol for the duration of the study.
  15. Men who are unwilling to comply with contraception methods as outlined in the protocol for the duration of the study.
  16. Investigator site staff or Pfizer employees directly involved in the conduct of the study, site staff otherwise supervised by the investigator, and their respective family members.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1,028 participants (actual)

Study arms

  • Experimental
    RSVpreF vaccine Group 1

    RSVpreF

    Biological: RSVpreF (Group 1)

  • Experimental
    RSVpreF vaccine Group 2

    RSVpreF

    Biological: RSVpreF (Group 2)

  • Experimental
    RSVpreF vaccine Group 3

    RSVpreF

    Biological: RSVpreF (Group 3)

  • Placebo comparator
    Placebo dose

    Placebo

    Biological: Placebo

Interventions

  • BiologicalRSVpreF (Group 1)

    RSV vaccine (RSVpreF)

  • BiologicalRSVpreF (Group 2)

    RSV vaccine (RSVpreF)

  • BiologicalRSVpreF (Group 3)

    RSV vaccine (RSVpreF)

  • BiologicalPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Geometric Mean Ratios (GMRs) of Respiratory Syncytial Virus Subgroup A (RSV A) and B (RSV B) Neutralizing Antibodies at 1 Month After Vaccination for Every Pair of RSVpreF Lots

    Geometric mean titer (GMT) of RSV A and RSV B neutralizing antibodies were calculated by exponentiating the mean logarithm of the titers and the corresponding 95% confidence interval (CI) was based on the Student t distribution. GMTs were reported in the descriptive section. Geometric mean ratios (GMRs) for each RSV vaccine lot comparison (Group 1/Group 2, Group 1/Group 3, and Group 2/Group 3) for RSV A and RSV B neutralizing antibody titers was calculated and reported in statistical analysis.

    Time frame: 1 month (27 to 42 days window) after vaccination on Day 1

  2. Percentage of Participants With Local Reactions Within 7 Days After Vaccination

    Local reactions included pain at injection site, redness and swelling and were recorded by participants in an electronic diary (e-diary). Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 centimeter (cm) and graded as mild: greater than (\>) 2.0 to 5.0 cm, moderate: \>5.0 to 10.0 cm and severe: \>10.0 cm. Pain at injection site was graded as mild: did not interfere with activity, moderate: interfered with activity and severe: prevented daily activity. Exact 2-sided 95% CI was based on the Clopper and Pearson method.

    Time frame: Within 7 days after vaccination on Day 1

  3. Percentage of Participants With Systemic Events Within 7 Days After Vaccination

    Systemic events included fever, fatigue, headache, nausea, muscle pain, joint pain, vomiting, diarrhea and were recorded by participants in an e-diary. Fever was defined as temperature greater than or equal to (\>=)38.0 degrees Celsius (C) and categorized as mild (\>=38.0 to 38.4 degrees C), moderate (\>38.4 to 38.9 degrees C) and severe (\>38.9 to 40.0 degrees C). Fatigue, headache, nausea, muscle pain and joint pain were graded as mild: did not interfere with activity, moderate: some interference with activity and severe: prevented daily routine activity. Vomiting was graded as mild: 1 to 2 times in 24 hours (h), moderate: \>2 times in 24h and severe: required intravenous hydration. Diarrhea was graded as mild: 2 to 3 loose stools in 24h, moderate: 4 to 5 loose stools in 24h and severe: 6 or more loose stools in 24h. Exact 2-sided 95% CI was based on the Clopper and Pearson method.

    Time frame: Within 7 days after vaccination on Day 1

  4. Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    An AE was any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. AEs included both serious and all non-serious adverse events excluding local reactions and systemic events. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; required inpatient hospitalization or prolongation of existing hospitalization; life-threatening ; persistent or significant disability/incapacity; congenital anomaly/birth defect and suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic. Exact 2-sided 95% CI was based on the Clopper and Pearson method.

    Time frame: Day of consent (Day 1) through study completion (approximately 1 Month)

07

Results

Posted Apr 12, 2023

Participant flow

Participant flow — Overall Study
MilestonePlaceboGroup 1: RSVpreF Lot 1Group 2: RSVpreF Lot 2Group 3: RSVpreF Lot 3
Started247249247250
Vaccinated247249247249
Completed243243239245
Not completed4685
Withdrew: Lost to follow-up3552
Withdrew: Withdrawal by subject0123
Withdrew: No longer met eligibility criteria1000
Withdrew: Other0010

Outcome measures

PrimaryGeometric Mean Ratios (GMRs) of Respiratory Syncytial Virus Subgroup A (RSV A) and B (RSV B) Neutralizing Antibodies at 1 Month After Vaccination for Every Pair of RSVpreF Lots

Geometric mean titer (GMT) of RSV A and RSV B neutralizing antibodies were calculated by exponentiating the mean logarithm of the titers and the corresponding 95% confidence interval (CI) was based on the Student t distribution. GMTs were reported in the descriptive section. Geometric mean ratios (GMRs) for each RSV vaccine lot comparison (Group 1/Group 2, Group 1/Group 3, and Group 2/Group 3) for RSV A and RSV B neutralizing antibody titers was calculated and reported in statistical analysis.

Time frame:
1 month (27 to 42 days window) after vaccination on Day 1
Reported as:
Geometric mean · Titer
Geometric Mean Ratios (GMRs) of Respiratory Syncytial Virus Subgroup A (RSV A) and B (RSV B) Neutralizing Antibodies at 1 Month After Vaccination for Every Pair of RSVpreF Lots
TiterGroup 1: RSVpreF Lot 1Group 2: RSVpreF Lot 2Group 3: RSVpreF Lot 3
RSV A25238.1 (22867.7 to 27854.2)25207.5 (22360.8 to 28416.6)24130.9 (21536.3 to 27038.1)
RSV B21701.9 (19433.1 to 24235.6)20317.3 (17944.4 to 23003.9)19238.1 (16920.0 to 21873.9)
Statistical analysis
  • Group 1: RSVpreF Lot 1 vs Group 2: RSVpreF Lot 2 · Geometric mean ratio: 1.00 · 95% CI 0.858 to 1.169GMRs and 2-sided CIs were calculated by exponentiating the difference in least-square (LS) means and corresponding CIs based on analysis of logarithmically transformed assay results using a linear regression model.
  • Group 1: RSVpreF Lot 1 vs Group 3: RSVpreF Lot 3 · Geometric mean ratio: 1.05 · 95% CI 0.900 to 1.215GMRs and 2-sided CIs were calculated by exponentiating the difference in LS means and corresponding CIs based on analysis of logarithmically transformed assay results using a linear regression model.
  • Group 2: RSVpreF Lot 2 vs Group 3: RSVpreF Lot 3 · Geometric mean ratio: 1.04 · 95% CI 0.886 to 1.232GMRs and 2-sided CIs were calculated by exponentiating the difference in LS means and corresponding CIs based on analysis of logarithmically transformed assay results using a linear regression model.
  • Group 1: RSVpreF Lot 1 vs Group 2: RSVpreF Lot 2 · Geometric mean ratio: 1.07 · 95% CI 0.905 to 1.261GMRs and 2-sided CIs were calculated by exponentiating the difference in LS means and corresponding CIs based on analysis of logarithmically transformed assay results using a linear regression model.
  • Group 1: RSVpreF Lot 1 vs Group 3: RSVpreF Lot 3 · Geometric mean ratio: 1.13 · 95% CI 0.953 to 1.336GMRs and 2-sided CIs were calculated by exponentiating the difference in LS means and corresponding CIs based on analysis of logarithmically transformed assay results using a linear regression model.
  • Group 2: RSVpreF Lot 2 vs Group 3: RSVpreF Lot 3 · Geometric mean ratio: 1.06 · 95% CI 0.884 to 1.262GMRs and 2-sided CIs were calculated by exponentiating the difference in LS means and corresponding CIs based on analysis of logarithmically transformed assay results using a linear regression model.
PrimaryPercentage of Participants With Local Reactions Within 7 Days After Vaccination

Local reactions included pain at injection site, redness and swelling and were recorded by participants in an electronic diary (e-diary). Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 centimeter (cm) and graded as mild: greater than (\>) 2.0 to 5.0 cm, moderate: \>5.0 to 10.0 cm and severe: \>10.0 cm. Pain at injection site was graded as mild: did not interfere with activity, moderate: interfered with activity and severe: prevented daily activity. Exact 2-sided 95% CI was based on the Clopper and Pearson method.

Time frame:
Within 7 days after vaccination on Day 1
Reported as:
Number · Percentage of participants
Percentage of Participants With Local Reactions Within 7 Days After Vaccination
Percentage of participantsPlaceboRSVpreF Pooled Lots (Groups 1, 2 and 3)
Pain at injection site: Mild10.5 (7.0 to 15.0)31.5 (28.2 to 35.0)
Pain at injection site: Moderate0.8 (0.1 to 2.9)5.4 (3.9 to 7.3)
Pain at injection site: Severe0 (0.0 to 1.5)0 (0.0 to 0.5)
Redness: Mild0.4 (0.0 to 2.2)4.4 (3.1 to 6.2)
Redness: Moderate0.4 (0.0 to 2.2)2.8 (1.8 to 4.3)
Redness: Severe0 (0.0 to 1.5)0.5 (0.1 to 1.4)
Swelling: Mild0.4 (0.0 to 2.2)4.0 (2.7 to 5.7)
Swelling: Moderate0 (0.0 to 1.5)3.8 (2.5 to 5.4)
Swelling: Severe0 (0.0 to 1.5)0 (0.0 to 0.5)
PrimaryPercentage of Participants With Systemic Events Within 7 Days After Vaccination

Systemic events included fever, fatigue, headache, nausea, muscle pain, joint pain, vomiting, diarrhea and were recorded by participants in an e-diary. Fever was defined as temperature greater than or equal to (\>=)38.0 degrees Celsius (C) and categorized as mild (\>=38.0 to 38.4 degrees C), moderate (\>38.4 to 38.9 degrees C) and severe (\>38.9 to 40.0 degrees C). Fatigue, headache, nausea, muscle pain and joint pain were graded as mild: did not interfere with activity, moderate: some interference with activity and severe: prevented daily routine activity. Vomiting was graded as mild: 1 to 2 times in 24 hours (h), moderate: \>2 times in 24h and severe: required intravenous hydration. Diarrhea was graded as mild: 2 to 3 loose stools in 24h, moderate: 4 to 5 loose stools in 24h and severe: 6 or more loose stools in 24h. Exact 2-sided 95% CI was based on the Clopper and Pearson method.

Time frame:
Within 7 days after vaccination on Day 1
Reported as:
Number · Percentage of participants
Percentage of Participants With Systemic Events Within 7 Days After Vaccination
Percentage of participantsPlaceboRSVpreF Pooled Lots (Groups 1, 2 and 3)
Fever: Mild0.4 (0.0 to 2.2)0.8 (0.3 to 1.8)
Fever: Moderate0.4 (0.0 to 2.2)0.9 (0.4 to 1.9)
Fever: Severe0 (0.0 to 1.5)0.3 (0.0 to 1.0)
Fatigue: Mild19.4 (14.7 to 24.9)21.3 (18.4 to 24.4)
Fatigue: Moderate12.6 (8.7 to 17.3)21.0 (18.1 to 24.1)
Fatigue: Severe1.2 (0.3 to 3.5)0.4 (0.1 to 1.2)
Headache: Mild18.2 (13.6 to 23.6)21.3 (18.4 to 24.4)
Headache: Moderate10.1 (6.7 to 14.6)14.8 (12.3 to 17.6)
Headache: Severe0 (0.0 to 1.5)0.1 (0.0 to 0.7)
Nausea: Mild4.5 (2.2 to 7.8)6.3 (4.7 to 8.3)
Nausea: Moderate2.4 (0.9 to 5.2)4.2 (2.9 to 5.9)
Nausea: Severe0 (0.0 to 1.5)0 (0.0 to 0.5)
Vomiting: Mild0.4 (0.0 to 2.2)1.1 (0.5 to 2.1)
Vomiting: Moderate0 (0.0 to 1.5)0.5 (0.1 to 1.4)
Vomiting: Severe0 (0.0 to 1.5)0 (0.0 to 0.5)
Diarrhea: Mild5.7 (3.1 to 9.3)8.9 (6.9 to 11.2)
Diarrhea: Moderate4.9 (2.5 to 8.3)4.2 (2.9 to 5.9)
Diarrhea: Severe0.4 (0.0 to 2.2)0.4 (0.1 to 1.2)
Muscle Pain: Mild7.7 (4.7 to 11.8)17.3 (14.6 to 20.2)
Muscle Pain: Moderate3.2 (1.4 to 6.3)12.3 (10.0 to 14.8)
Muscle Pain: Severe0 (0.0 to 1.5)0.1 (0.0 to 0.7)
Joint Pain: Mild2.8 (1.1 to 5.8)8.2 (6.3 to 10.4)
Joint Pain: Moderate1.6 (0.4 to 4.1)6.7 (5.0 to 8.8)
Joint Pain: Severe0 (0.0 to 1.5)0 (0.0 to 0.5)
PrimaryPercentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

An AE was any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. AEs included both serious and all non-serious adverse events excluding local reactions and systemic events. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; required inpatient hospitalization or prolongation of existing hospitalization; life-threatening ; persistent or significant disability/incapacity; congenital anomaly/birth defect and suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic. Exact 2-sided 95% CI was based on the Clopper and Pearson method.

Time frame:
Day of consent (Day 1) through study completion (approximately 1 Month)
Reported as:
Number · Percentage of participants
Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Percentage of participantsPlaceboRSVpreF Pooled Lots (Groups 1, 2 and 3)
AE6.1 (3.4 to 9.8)5.8 (4.2 to 7.7)
SAE0 (0.0 to 1.5)0 (0.0 to 0.5)

Adverse events

Collected over Local reactions and systemic events (systematic assessment): within 7 days after vaccination on Day 1; AEs and SAEs (non-systematic assessment) and all-cause mortality: Day of consent (Day 1) through study completion (approximately 1 Month). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/247 (0%)0/247 (0%)130/247 (52.6%)
Group 1: RSVpreF Lot 10/249 (0%)0/249 (0%)170/249 (68.3%)
Group 2: RSVpreF Lot 20/247 (0%)0/247 (0%)172/247 (69.6%)
Group 3: RSVpreF Lot 30/249 (0%)0/249 (0%)166/249 (66.7%)
RSVpreF Pooled Lots (Groups 1, 2 and 3)0/745 (0%)0/745 (0%)508/745 (68.2%)
Most frequent other events
Showing 10 of 62
Most frequent other events
EventPlaceboGroup 1: RSVpreF Lot 1Group 2: RSVpreF Lot 2Group 3: RSVpreF Lot 3RSVpreF Pooled Lots (Groups 1, 2 and 3)
Fatigue (FATIGUE)General disorders82/247107/249103/247107/249317/745
Injection site pain (PAIN AT INJECTION SITE)General disorders28/24783/24997/24794/249274/745
Headache (HEADACHE)Nervous system disorders70/24795/24988/24786/249269/745
Myalgia (MUSCLE PAIN)Musculoskeletal and connective tissue disorders27/24768/24982/24770/249220/745
Arthralgia (JOINT PAIN)Musculoskeletal and connective tissue disorders11/24737/24935/24739/249111/745
Diarrhoea (DIARRHEA)Gastrointestinal disorders27/24735/24938/24727/249100/745
Nausea (NAUSEA)Gastrointestinal disorders17/24723/24929/24726/24978/745
Swelling (SWELLING)General disorders1/24711/24923/24724/24958/745
Erythema (REDNESS)Skin and subcutaneous tissue disorders2/24711/24923/24724/24958/745
Pyrexia (FEVER)General disorders2/2474/2497/2474/24915/745

Baseline characteristics

Safety population included all randomized participants who received study intervention.

Age, Continuous
Age, Continuous(Years)PlaceboGroup 1: RSVpreF Lot 1Group 2: RSVpreF Lot 2Group 3: RSVpreF Lot 3Total
Mean34.46 ± 8.7334.16 ± 8.5833.81 ± 9.0233.90 ± 9.0234.08 ± 8.83
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboGroup 1: RSVpreF Lot 1Group 2: RSVpreF Lot 2Group 3: RSVpreF Lot 3Total
Female140138158157593
Male1071118992399
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboGroup 1: RSVpreF Lot 1Group 2: RSVpreF Lot 2Group 3: RSVpreF Lot 3Total
Hispanic or Latino60656855248
Not Hispanic or Latino185180174189728
Unknown or Not Reported245516
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboGroup 1: RSVpreF Lot 1Group 2: RSVpreF Lot 2Group 3: RSVpreF Lot 3Total
American Indian or Alaska Native22228
Asian6167938
Native Hawaiian or Other Pacific Islander10146
Black or African American48535350204
White178169177179703
More than one race745117
Unknown or Not Reported552416
08

Study locations

18 sites
  • Global Health Research Center, Inc.
    Miami Lakes, Florida 33016, United States
  • Precision Clinical Research
    Sunrise, Florida 33351, United States
  • Clinical Site Partners, Inc
    Winter Park, Florida 32789, United States
  • Clinical Site Partners
    Winter Park, Florida 32789, United States
  • Clinical Research Atlanta
    Stockbridge, Georgia 30281, United States
  • East-West Medical Research Institute
    Honolulu, Hawaii 96814, United States
  • Clinical Research Prime
    Idaho Falls, Idaho 83404, United States
  • Kentucky Pediatric/ Adult Research
    Bardstown, Kentucky 40004, United States
  • Sundance Clinical Research
    Saint Louis, Missouri 63141, United States
  • Meridian Clinical Research, LLC
    Omaha, Nebraska 68134, United States
  • Accellacare - Wilmington
    Wilmington, North Carolina 28401, United States
  • Aventiv Research Inc
    Columbus, Ohio 43213, United States
  • Velocity Clinical Research, Providence
    East Greenwich, Rhode Island 02818, United States
  • Benchmark Research
    Austin, Texas 78705, United States
  • Texas Center for Drug Development, Inc.
    Houston, Texas 77081, United States
  • DM Clinical Research
    Tomball, Texas 77375, United States
  • J. Lewis Research, Inc. / Foothill Family Clinic
    Salt Lake City, Utah 84109, United States
  • J. Lewis Research, Inc. / Foothill Family Clinic South
    Salt Lake City, Utah 84121, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2021 to primary completion in Apr 2022, 5 months.

Results were first posted in Apr 2023, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 14, 2021
First posted
Oct 27, 2021
StartActual
Oct 21, 2021
Primary completionActual
Apr 4, 2022
CompletionActual
Apr 4, 2022
Results first posted
Apr 12, 2023
Last update
Apr 12, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 12, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05096208
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Oct 27, 2021
Start date
Oct 21, 2021
Primary completion
Apr 4, 2022
Completion
Apr 4, 2022
Results posted
Apr 12, 2023
Last update
Apr 12, 2023

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion